253 related articles for article (PubMed ID: 21325111)
1. Cost-utility of aspirin and proton pump inhibitors for primary prevention.
Earnshaw SR; Scheiman J; Fendrick AM; McDade C; Pignone M
Arch Intern Med; 2011 Feb; 171(3):218-25. PubMed ID: 21325111
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
3. Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance.
de Groot NL; van Haalen HG; Spiegel BM; Laine L; Lanas A; Focks JJ; Siersema PD; van Oijen MG
Cardiovasc Drugs Ther; 2013 Aug; 27(4):341-57. PubMed ID: 23417566
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.
Takabayashi N; Murata K; Tanaka S; Kawakami K
Pharmacoeconomics; 2015 Oct; 33(10):1091-100. PubMed ID: 25995130
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
Saini SD; Fendrick AM; Scheiman JM
Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
[TBL] [Abstract][Full Text] [Related]
6. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands.
Chau SH; Sluiter RL; Kievit W; Wensing M; Teichert M; Hugtenburg JG
Drugs Aging; 2017 May; 34(5):375-386. PubMed ID: 28361278
[TBL] [Abstract][Full Text] [Related]
8. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.
Pignone M; Earnshaw S; Tice JA; Pletcher MJ
Ann Intern Med; 2006 Mar; 144(5):326-36. PubMed ID: 16520473
[TBL] [Abstract][Full Text] [Related]
9. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
[TBL] [Abstract][Full Text] [Related]
10. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.
Vaduganathan M; Bhatt DL; Cryer BL; Liu Y; Hsieh WH; Doros G; Cohen M; Lanas A; Schnitzer TJ; Shook TL; Lapuerta P; Goldsmith MA; Laine L; Cannon CP;
J Am Coll Cardiol; 2016 Apr; 67(14):1661-71. PubMed ID: 27012778
[TBL] [Abstract][Full Text] [Related]
11. [Economic evaluation of the treatment with aspirin plus esomeprazole compared to clopidogrel in gastrointestinal bleeding prevention].
Piñol C
Gac Sanit; 2006; 20(1):54-7. PubMed ID: 16539994
[TBL] [Abstract][Full Text] [Related]
12. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.
Morneau KM; Reaves AB; Martin JB; Oliphant CS
J Manag Care Pharm; 2014 Feb; 20(2):187-93. PubMed ID: 24456320
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
Tsai YW; Wen YW; Huang WF; Chen PF; Kuo KN; Hsiao FY
J Gastroenterol; 2011 Jan; 46(1):39-45. PubMed ID: 20811753
[TBL] [Abstract][Full Text] [Related]
14. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
15. Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.
Sylvester KW; Cheng JW; Mehra MR
Vasc Health Risk Manag; 2013; 9():245-54. PubMed ID: 23696706
[TBL] [Abstract][Full Text] [Related]
16. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Schleinitz MD; Heidenreich PA
Ann Intern Med; 2005 Feb; 142(4):251-9. PubMed ID: 15710958
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of providing full drug coverage to increase medication adherence in post-myocardial infarction Medicare beneficiaries.
Choudhry NK; Patrick AR; Antman EM; Avorn J; Shrank WH
Circulation; 2008 Mar; 117(10):1261-8. PubMed ID: 18285564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
